Mia, a deep learning artificial intelligence (AI) solution that works with radiologists to improve breast cancer detection, avoid unnecessary biopsies and ultimately improve the patient experience for all women is being launched in the UAE.
On the sidelines of Arab Health 2021, UK-based Kheiron Medical Technologies signed an agreement with Atlas Medical, a medical device and pharma distributor focused on bringing state-of-the-art healthcare technology to the UAE. As part of the agreement, Atlas will bring Kheiron’s Mia solution to the UAE market. With patented AI technology developed on more than three million breast images, Mia (Mammography Intelligent Assessment) is designed to support breast radiologists in making the critical decision to recall women for further testing based on their mammography screening.
Mia is the first solution of its kind to receive the CE (European regulatory clearance) mark for use as an AI-enabled independent reader for the detection of breast cancer. Through rigorous clinical studies and testing, Mia has learnt to read mammograms to the same level of detail as a consulting radiologist.
In double-reading mammography workflows where scans are reviewed by two radiologists, Mia can be deployed independently alongside a single human reader. This delivers the quality improvements needed to ensure the sustainability of breast screening services and frees up clinicians to spend more time with patients. Mia can also be deployed as a concurrent reader or in double reader triage.
Mia will be available to the UAE, Qatar and Oman markets pending local requirements.
